KYMR News - Candlesense

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

(NASDAQ:KYMR) WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecul...

Leadership

11 days ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medi...

Investor

18 days ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile

What macro or sector‑specific factors could amplify or dampen the market reaction to Kymera’s Q2 results and KT-621 update? Are there any partnership or licensing opportunities emerging from the KT-621 data that could provide additional upside or upside risk? How might the oral delivery advantage of KT-621 impact pricing strategy and market adoption versus injectable therapies like dupilumab?

Earnings

about 1 month ago